Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» RNAi
RNAi
Roche, Alnylam Ink Potential $2.8B RNAi Partnership for Hypertension
Roche, Alnylam Ink Potential $2.8B RNAi Partnership for Hypertension
BioSpace
Roche
Alnylam
RNAi
hypertension
zilebesiran
Flag link:
AAIC: First Clinical Data from an RNAi Therapeutic for Alzheimer’s Continue to Impress
AAIC: First Clinical Data from an RNAi Therapeutic for Alzheimer’s Continue to Impress
BioSpace
AAIC
Alnylam
RNAi
Alzheimer's disease
ALN-APP
clinical trials
Flag link:
4DMT provides clinical programme updates for its wet AMD gene therapy
4DMT provides clinical programme updates for its wet AMD gene therapy
Clinical Trials Arena
4D Molecular Therapeutics
wet age-related macular degeneration
RNAi
4D-150
Flag link:
Janssen Returns Phase I NASH Candidate to Arrowhead
Janssen Returns Phase I NASH Candidate to Arrowhead
BioSpace
JNJ
Janssen
RNAi
Arrowhead Pharmaceuticals
NASH
Flag link:
Alnylam scraps trial in rare eye disorder, blaming drug price reforms
Alnylam scraps trial in rare eye disorder, blaming drug price reforms
Pharmaphorum
Alnylam
RNAi
vutrisiran
Stargardt disease
Inflation Reduction Act
drug pricing
Flag link:
Biotech’s near-term key catalysts
Biotech’s near-term key catalysts
EP Vantage
Biogen
Eisai
Alzheimer's disease
Arrowhead Pharmaceuticals
Takeda
RNAi
Madrigal
NASH
Ascendis
FDA
Flag link:
Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
Businesswire
Alnylam Pharmaceuticals
clinical trials
cemdisiran
Regeneron
IgAN
immunoglobultin A nephropathy
RNAi
Flag link:
Alnylam's potential fourth RNAi approval delayed three months, but impact likely to be 'modest'
Alnylam's potential fourth RNAi approval delayed three months, but impact likely to be 'modest'
Endpoints
Alnylam
RNAi
FDA
vutrisiran
Flag link:
Another biotech shuffles its C-suite as Silence CEO steps down
Another biotech shuffles its C-suite as Silence CEO steps down
Endpoints
Silence Therapeutics
Pharma CEOs
RNAi
Flag link:
GlaxoSmithKline takes aim at NASH, penning a $1B pact with RNAi biotech Arrowhead
GlaxoSmithKline takes aim at NASH, penning a $1B pact with RNAi biotech Arrowhead
Fierce Biotech
GSK
Arrowhead Pharmaceuticals
NASH
RNAi
Flag link:
Novo Nordisk bets big on RNAi, paying $3.3B to buy Dicerna
Novo Nordisk bets big on RNAi, paying $3.3B to buy Dicerna
Fierce Biotech
Novo Nordisk
M&A
Dicerna Pharmaceuticals
RNAi
Flag link:
Dicerna's RNAi drug shows 'inconsistent' results in rare kidney disease, tanking shares despite trial win
Dicerna's RNAi drug shows 'inconsistent' results in rare kidney disease, tanking shares despite trial win
Endpoints
Dicerna
RNAi
Primary Hyperoxaluria
clinical trials
Flag link:
Alnylam's Study on Renal Treatment Shows Promising Results In Phase III Trial
Alnylam's Study on Renal Treatment Shows Promising Results In Phase III Trial
BioSpace
Alnylam
RNAi
renal decline
clinical trials
lumasiran
Flag link:
Arrowhead rocked by animal tox issues again, hitting the pause button on RNAi study in cystic fibrosis
Arrowhead rocked by animal tox issues again, hitting the pause button on RNAi study in cystic fibrosis
Endpoints
Arrowhead Pharmaceuticals
RNAi
animal research
cystic fibrosis
Flag link:
Eli Lilly Collab Scores IND Approval for Dicerna's RNAi Cardiometabolic Drug
Eli Lilly Collab Scores IND Approval for Dicerna's RNAi Cardiometabolic Drug
BioSpace
Dicerna
Eli Lilly
LY3819469
clinical trials
RNAi
cardiometabolic diseases
Flag link:
Novartis’s big wager on RNAi approaches the finish line
Novartis’s big wager on RNAi approaches the finish line
EP Vantage
Novartis
RNAi
COVID-19
Leqvio
cholesterol
Flag link:
Can Either of These Little-Known Biotechs Find New Life Fighting Coronavirus?
Can Either of These Little-Known Biotechs Find New Life Fighting Coronavirus?
Motley Fool
Alnylam
Vir Biotechnology
RNAi
vaccines
COVID-19
Flag link:
Takeda drops $300M cash to kick off $1B RNAi alliance with Arrowhead, shooting for first-in-class rare disease drug
Takeda drops $300M cash to kick off $1B RNAi alliance with Arrowhead, shooting for first-in-class rare disease drug
Endpoints
Takeda
RNAi
Arrowhead Pharmaceuticals
Rare Diseases
Flag link:
Alnylam phase 3 links lumasiran to 'clinically significant' improvement in infants
Alnylam phase 3 links lumasiran to 'clinically significant' improvement in infants
Fierce Biotech
Alnylam
clinical trials
lumasiran
RNAi
PH1
Flag link:
Arrowhead Pharma Shares Soar on Early Liver Data for RNAi Drug
Arrowhead Pharma Shares Soar on Early Liver Data for RNAi Drug
Xconomy
Arrowhead Pharmaceuticals
clinical trials
liver disease
RNAi
ARO-AAT
Flag link:
Pages
1
2
3
4
5
6
next ›
last »